Compare ENTX & BOOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | BOOM |
|---|---|---|
| Founded | 2010 | 1965 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 141.8M |
| IPO Year | 2015 | 1995 |
| Metric | ENTX | BOOM |
|---|---|---|
| Price | $2.78 | $7.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $8.50 |
| AVG Volume (30 Days) | ★ 3.5M | 208.9K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.02 |
| EPS | ★ 0.07 | N/A |
| Revenue | $42,000.00 | ★ $609,840,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | $41.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $4.69 |
| 52 Week High | $4.20 | $9.20 |
| Indicator | ENTX | BOOM |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 65.31 |
| Support Level | $1.26 | $6.65 |
| Resistance Level | $3.22 | $7.40 |
| Average True Range (ATR) | 0.36 | 0.49 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 40.43 | 88.58 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.